GlassScriptPhysician profile
Bridget Wilburn
NPI 1588133730
$1,979.71
in general payments reported to CMS, 2019-2025
24 companies · $63.92 in 2025
The $63.92 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.42 · 2022: $453 · 2023: $440 · 2024: $985 · 2025: $63.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $557.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $692.84 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $228.60 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $142.99 | 2022-2023 | Minimed 780g |
| Novo Nordisk INC | $131.68 | 2022-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $100.92 | 2022-2025 | |
| Lilly USA, LLC | $99.53 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.73 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $79.71 | 2022-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $60.52 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $49.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.63 | 2023 | |
| Xeris Pharmaceuticals, INC. | $38.05 | 2022-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.35 | 2024 | Trulance, Xifaxan |
| Angiodynamics, INC. | $28.81 | 2025 | Nanoknife |
| Inspire Medical Systems, INC. | $22.50 | 2024 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $22.00 | 2021 | |
| Merck Sharp & Dohme LLC | $17.65 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Mylan Specialty L.P. | $17.25 | 2024 | Yupelri |
| Biogen, INC. | $16.88 | 2024 | Tysabri, Vumerity |
| Neurocrine Biosciences, INC. | $15.85 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.42 | 2021 | |
| Insulet Corporation | $14.06 | 2024 | Omnipod |
| Amgen INC. | $14.06 | 2023 | Prolia, Evenity |
| Pfizer INC. | $13.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Wilburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.